James WildingUK & European Patent Attorney
James is a UK & European Patent Attorney, who's practice is focused on EPO prosecution and opposition work in the life sciences sector. He also has extensive experience with supplementary protection certificates (SPCs) and has prosecuted SPC applications covering a number of blockbuster drugs.
Year joined: 2014
Qualifications: MBiochem DPhil EPA CPA
James handles a mix of EPO prosecution and opposition work in the life sciences sector. He has particular expertise in immunology, including antibody-based therapeutics and vaccines, diagnostics, nucleic acid amplification, (oligo) nucleotide therapy, gene editing and plant extracts. He is experienced in handling EPO opposition proceedings and regularly appears before EPO tribunals on behalf of clients. James also has extensive experience with supplementary protection certificates. He has co-ordinated prosecution of several SPC/paediatric extension portfolios across Europe, and regularly advises clients in this area, including in relation to SPC disputes.
James has a master's degree in biochemistry and a doctorate on the biochemistry of heart disease, both from Oxford University. James also conducted post-doctoral research at Université Paris-XI on cardiac disease. He is an author of several peer-reviewed papers on this subject.
Membership & Organisations
James is a CIPA fellow and member of the EPI.
Opponent against EP-B-2101823. After running extensive non-enablement arguments, the patent was revoked under this ground (June 2019). Opponent 1 in ten-way opposition against EP-B-2175884. Our arguments caught patentee in an inescapable added matter/extension of protection trap, resulting in revocation (December 2018). Represented patentee in the successful defence of EP-B-1301538 relating to artificial antibody scaffolds (April 2018). Represented opponent in the widely-reported CRISPR-Cas9 case in which the EPO ordered revocation of EP-B-2771468 belonging to the Broad Institute, et al. (January 2018).
- Patent Enforcement
- Patent Portfolio Management
- Patent Oppositions
- IP Strategy
- Freedom to Operate
- Due Diligence